Commercial developmentNot yet assessedWe only state a stage once a source supports it. Having a product on sale does not show it works or makes money.
Investment accessNo accessible investment route verifiedPast private offerings were limited to eligible investors. They are records of earlier sales, not open offers. · checked Oct 28, 2026

Evidence is labelled on each development below (company-reported, regulatory filing or government record), not on the company as a whole. Coverage is not an offer to invest. Private ownership does not imply available shares. Next scheduled recheck: Nov 27, 2026.

0developments published
—US federal obligations on record
2private-offering notices since 2019
Date not statedlatest development

Timeline

Nothing published for Colossal Biosciences yet. That can simply mean nothing material was filed or awarded in our coverage window.

Profile

Legal name
Colossal Biosciences Inc.
Incorporated
DE
Coverage
Offering notices + any filings + federal awards

Watch Colossal Biosciences

Anything new from Colossal Biosciences lands in your digest, with the source beside it. Following is about information, never an investment action. Up to 10 companies or frontiers on Pro, $49/month.

Follow this companyPreview a sample digest

Private offerings reported to the SEC (Form D)

A Form D is a notice a company files after selling securities without a public registration. Amount sold is cumulative for that offering as reported by the company; an amendment (D/A) updates an earlier notice, so rows are not added together. None of these is a valuation or an open offer.

FiledFormAmount soldOffering sizeFirst saleInvestorsExemptionRecord
Jul 23, 2024D/A$163 million$174 millionJan 27, 202327Rule 506(b)SEC ↗
Feb 10, 2023D$150 million$150 millionJan 27, 202315Rule 506(b)SEC ↗